Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate

Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate

2026.01.25
Radical prostatectomy (RP) remains the primary surgical treatment for localized prostate cancer. However, a substantial proportion of patients experience biochemical recurrence (BCR) following surgery, which is closely associated with disease progression and prostate cancer–specific mortality. Consequently, reducing postoperative BCR and improving long-term outcomes in prostate cancer patients have become major areas of clinical research focus.
Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment

Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment

2026.01.23
A multidisciplinary team led by Professors Xuesong Li and Qi  Tangfrom the Institute of Urology and Department of Urology, Peking University First Hospital, in collaboration with Professor  Jianhua  Zhang’s team from the Department of Nuclear Medicine and Professor  Xiaoying Li’s team from the Department of Radiation Oncology, has published an original research article in Clinical Nuclear Medicine (Impact Factor: 9.6), the official journal of the Society of Nuclear Medicine and Molecular Imaging.
Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival

Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival

2026.01.23
In 2025, the 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai. The meeting brought together leading experts in urologic oncology from China and around the world to engage in in-depth discussions on advances in the diagnosis and treatment of urothelial carcinoma, prostate cancer, renal cell carcinoma, and other major genitourinary malignancies.
2025 Yat-sen Breast Cancer Conference丨Professor Jing Yao: Addressing the Multiple Unique Needs of Young Breast Cancer Patients and Optimizing Treatment Choices Through Patient-Centered Care

2025 Yat-sen Breast Cancer Conference丨Professor Jing Yao: Addressing the Multiple Unique Needs of Young Breast Cancer Patients and Optimizing Treatment Choices Through Patient-Centered Care

2026.01.20
The 2025 Yat-sen Breast Cancer Conference, held in conjunction with the 2025 CSCO BC Southern Forum, the Second National Conference on the Release of the Chinese Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer, and the Fourth Yat-sen Breast Nursing Conference, took place in Guangzhou from December 26 to 27, 2025. The meeting focused on standardized breast cancer care, the evolution of cutting-edge treatment strategies, and precision management of young breast cancer patients, systematically presenting the latest advances and future directions in the field. During the conference, Oncology Frontier invited Professor Jing Yao from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, to interpret the newly released Chinese Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer (2025 Edition), and to analyze the characteristics, treatment strategies, and evolving screening approaches for young breast cancer patients in China.